TY - JOUR
T1 - Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE)
AU - Ichiki, Takako
AU - Koga, Tomoaki
AU - Okuno, Toshiaki
AU - Saeki, Kazuko
AU - Yamamoto, Yasuhiko
AU - Yamamoto, Hiroshi
AU - Sakaguchi, Masakiyo
AU - Yokomizo, Takehiko
N1 - Funding Information:
The authors thank J. Miyazaki (Osaka University, Osaka, Japan) for supplying the pCXN2 expression vector (26), J. Takasaki (Astellas Pharmaceuticals, Tokyo, Japan) for supplying YM-254890 (35), and the members of our laboratories for advice and helpful discussions. T.I. is a Research Fellow of the Japan Society for the Promotion of Science. This work was supported by Grants-in-Aid for Scientific Research 22116001, 22116002, 15H05901, 15H05904, and 15H04708 (to T.Y.); 25860223 (to T.K.); 24590386 and 15K08316 (to K.S.); and 24102522 and 25460374 (to T.O.) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, and by the Naito Foundation, the Ono Medical Research Foundation, the Uehara Memorial Foundation, the Mitsubishi Foundation, and the Takeda Science Foundation. This study was supported in part by Grant-in-Aid (S1311011) from the Foundation of Strategic Research Projects in Private Universities from MEXT and a grant from the Institute for Environmental and Gender-Specific Medicine. The authors declare no conflicts of interest.
Funding Information:
The authors thank J. Miyazaki (Osaka University, Osaka, Japan) for supplying the pCXN2 expression vector ( 26 ), J. Takasaki (Astellas Pharmaceuticals, Tokyo, Japan) for supplying YM‐254890 ( 35 ), and the members of our laboratories for advice and helpful discussions. T.I. is a Research Fellow of the Japan Society for the Promotion of Science. This work was supported by Grants‐in‐Aid for Scientific Research 22116001, 22116002, 15H05901, 15H05904, and 15H04708 (to T.Y.); 25860223 (to T.K.); 24590386 and 15K08316 (to K.S.); and 24102522 and 25460374 (to T.O.) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, and by the Naito Foundation, the Ono Medical Research Foundation, the Uehara Memorial Foundation, the Mitsubishi Foundation, and the Takeda Science Foundation. This study was supported in part by Grant‐in‐Aid (S1311011) from the Foundation of Strategic Research Projects in Private Universities from MEXT and a grant from the Institute for Environmental and Gender‐Specific Medicine. The authors declare no conflicts of interest.
Publisher Copyright:
© FASEB
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Leukotriene B4 (LTB4) receptor 1 (BLT1), a high-affinity GPCR for LTB4, plays important roles in acute and chronic inflammatory diseases. Although the LTB4-BLT1 axis is known to promote inflammation, no studies have defined the binding proteins that modulate LTB4-BLT1 signaling. In this study, the receptor for advanced glycation end products (RAGE) interacted with BLT1 in human cervical epithelial HeLa cells. RAGE increased LTB4-BLT1-dependent ERK phosphorylation and inhibited LTB4-BLT1-dependent activation of NF-κB and up-regulation of proinflammatory cytokines and chemokines. RAGE-dependent inhibition of NF-κB was blunted by treatment with an MEK inhibitor, suggesting that RAGE suppresses LTB4-BLT1-dependent NF-κB signaling by enhancing the MEK-ERK pathway. Meanwhile, in a chemotaxis assay of mouse bone marrow-derived neutrophils, the velocity of LTB4-dependent neutrophil migration was attenuated by soluble RAGE, which is an inhibitory decoy protein for RAGE signaling, in a dose-dependent manner (0.2–5 μg/ml), or by RAGE deficiency. Furthermore, both LTB4-dependent ERK phosphorylation in neutrophils and LTB4-dependent neutrophil accumulation in a murine peritonitis model were significantly attenuated in RAGE-deficient mice compared with C57BL/6J wild-type mice, indicating that RAGE potentiates LTB4-dependent neutrophil migration by enhancing ERK phosphorylation. Our results demonstrate that RAGE interacts with BLT1 and modulates LTB4-BLT1 signaling through potentiation of the MEK-ERK pathway.—Ichiki, T., Koga, T., Okuno, T., Saeki K., Yamamoto, Y., Yamamoto, H., Sakaguchi, M., Yokomizo, T. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J. 30, 1811–1822 (2016). www.fasebj.org.
AB - Leukotriene B4 (LTB4) receptor 1 (BLT1), a high-affinity GPCR for LTB4, plays important roles in acute and chronic inflammatory diseases. Although the LTB4-BLT1 axis is known to promote inflammation, no studies have defined the binding proteins that modulate LTB4-BLT1 signaling. In this study, the receptor for advanced glycation end products (RAGE) interacted with BLT1 in human cervical epithelial HeLa cells. RAGE increased LTB4-BLT1-dependent ERK phosphorylation and inhibited LTB4-BLT1-dependent activation of NF-κB and up-regulation of proinflammatory cytokines and chemokines. RAGE-dependent inhibition of NF-κB was blunted by treatment with an MEK inhibitor, suggesting that RAGE suppresses LTB4-BLT1-dependent NF-κB signaling by enhancing the MEK-ERK pathway. Meanwhile, in a chemotaxis assay of mouse bone marrow-derived neutrophils, the velocity of LTB4-dependent neutrophil migration was attenuated by soluble RAGE, which is an inhibitory decoy protein for RAGE signaling, in a dose-dependent manner (0.2–5 μg/ml), or by RAGE deficiency. Furthermore, both LTB4-dependent ERK phosphorylation in neutrophils and LTB4-dependent neutrophil accumulation in a murine peritonitis model were significantly attenuated in RAGE-deficient mice compared with C57BL/6J wild-type mice, indicating that RAGE potentiates LTB4-dependent neutrophil migration by enhancing ERK phosphorylation. Our results demonstrate that RAGE interacts with BLT1 and modulates LTB4-BLT1 signaling through potentiation of the MEK-ERK pathway.—Ichiki, T., Koga, T., Okuno, T., Saeki K., Yamamoto, Y., Yamamoto, H., Sakaguchi, M., Yokomizo, T. Modulation of leukotriene B4 receptor 1 signaling by receptor for advanced glycation end products (RAGE). FASEB J. 30, 1811–1822 (2016). www.fasebj.org.
KW - GPCR
KW - chemotaxis
KW - lipid mediator
UR - http://www.scopus.com/inward/record.url?scp=84991674969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991674969&partnerID=8YFLogxK
U2 - 10.1096/fj.201500117
DO - 10.1096/fj.201500117
M3 - Article
C2 - 26813973
AN - SCOPUS:84991674969
SN - 0892-6638
VL - 30
SP - 1811
EP - 1822
JO - FASEB Journal
JF - FASEB Journal
IS - 5
ER -